In combination with PPARγ agonists, retinoids have been reported to enhance growth inhibition and cell death in human breast cancer cell lines in vitro (Elstner et al, 1998), possibly via interactive heterodimerisation of retinoid receptors and PPARγ. Here, PPARG is linked to breast carcinoma.